摘要

中国医药行业迎来'深度探索时刻'，全球25%的临床试验及西方药企三分之一的实验分子源自中国实验室，数量自2020年增长三倍。2017年起，监管改革如加入国际人用药品注册技术协调会(ICH)及实施60天'默示许可'审批制度，不仅简化了临床试验流程，还接纳外国数据，安进公司的XGEVA无需在中国重测即获批便是明证。临床试验数量从2017年的600项猛增至2023年的2000项，中国新药研发水平已逼近美国。40%的中国试验保持高入组率，而美国75%的试验因招募难题参与者不足百人。中美改革路径迥异：美国通过扩大医疗补助和简化行政程序推进，中国则依靠集中协调和加速审批。日韩印等国正借鉴中国模式，显示全球正寻求监管与创新的平衡。专家指出，快速获取人类数据反馈及政策协同将引领下一轮药物发现浪潮，中国监管的敏捷性正重塑全球生物医药格局。

China's pharmaceutical sector has achieved a "DeepSeek moment," with 25% of global clinical trials and a third of Western pharma’s experimental molecules now sourced from Chinese labs, tripling since 2020. Regulatory reforms since 2017, including joining the ICH and adopting a 60-day "implied license" approval system, enabled streamlined trials and acceptance of foreign data, exemplified by Amgen’s XGEVA approval without China retesting. Clinical trials surged from 600 to 2,000 annually (2017–2023), with China’s novel drug development nearing U.S. levels. High enrollment rates persist in 40% of Chinese trials, contrasting with 75% of U.S. trials recruiting under 100 participants due to recruitment challenges. Reform pathways differ: the U.S. focuses on Medicaid expansion and administrative simplification, while China leverages centralized coordination and accelerated approvals. Japan, South Korea, and India are emulating China’s model, highlighting the global shift toward balancing oversight and innovation. Experts emphasize that rapid human data feedback and policy alignment will determine the next wave of drug discovery, as China’s regulatory agility reshapes global biopharma dynamics.